Sanofi's Iniparib Fails Phase III Study, but Firm Investigating Benefit by Molecular Subtypes

"[Biomarker] analyses are underway to evaluate iniparib benefit within the intrinsic subtypes, as well as within other molecularly defined subpopulations," a study investigator said.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.